Remozen (remogliflozin etabonate) / Islet Sci, Kissei - LARVOL DELTA

The Safety Profile of Sodium-Glucose Co-transporter 2 Inhibitors in Type 2 Diabetes Mellitus With Special Reference to Genital Mycosis (ENDO 2025) - "The majority were prescribed Dapagliflozin (678), followed by Empagliflozin (61), Canagliflozin (4), and Remogliflozin (8). SGLT2 inhibitors are generally well tolerated, with genital infections (GM) and urinary tract infections (UTIs) being the most common side effects, which often contribute to hesitancy in their initiation. However, our study observed a lower incidence of these adverse events, particularly when SGLT2 inhibitors were combined with DPP4 inhibitors, which is likely explained because of better glycemic control and immunomodulatory actions of DPP$ inhibitors decreasing the adhesion of fungi to the genital mucosa. Furthermore, most of the reported side effects were manageable."

Clinical • Back Pain • Dermatology • Diabetes • Fatigue • Infectious Disease • Metabolic Disorders • Musculoskeletal Pain • Nephrology • Pain • Type 2 Diabetes Mellitus

IMPACT OF SGLT2INHIBITORS ON LEFT ATRIAL MECHANICS IN PATIENTS OF TYPE2 DIABETES MELLITUS WITH CHRONIC HEART FAILURE - Shantanu Sengupta (ACC 2025) - "This prospective study showed beneficial effect of Remogliflozin and Empagliflozin on LV volumes,LV diastolic parameters,LVGLS,RV systolic parameters and LA contractile strain in T2DM patients with CHF.This study showed for the first time that SGLT2inhibitors causes subtle changes in LA geometry and function."

Clinical • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus

The SGLT2 inhibitor remogliflozin induces vasodilation in the femoral artery of rabbits via activation of a Kv channel, the SERCA pump, and the cGMP signaling pathway. (PubMed, Toxicol Appl Pharmacol) - "Pretreatment with the Ca2+-sensitive K+ channel inhibitor (paxilline), the ATP-sensitive K+ channel inhibitor (glibenclamide), or the inwardly rectifying K+ channel inhibitor (Ba2+) did not alter the vasodilatory effect. However, pretreatment with the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA) pump inhibitors thapsigargin and cyclopiazonic acid effectively reduced the remogliflozin effect, as did pretreatment with cGMP/PKG-related but not cAMP/PKA-related signaling pathway inhibitors. These results indicate that remogliflozin-mediated dilation of the femoral artery occurs via the activation of Kv channels, mainly the Kv1.5 subtype, SERCA pump, and cGMP/PKG-related signaling pathways."

Journal • Preclinical

A prospective, multicentre study evaluating safety and efficacy of a fixed dose combination of Remogliflozin etabonate, Vildagliptin, and Metformin in Indian patients with type 2 diabetes mellitus (Triad-RMV). (PubMed, Clin Diabetes Endocrinol) - "The twice daily triple FDC of RMV was well tolerated, safe and effective in patients with Type 2 Diabetes Mellitus uncontrolled on dual drug therapy of Metformin plus SGLT2i or Metformin plus DPP4i. The treatment led to significant improvements in glycemic control and other metabolic parameters over 24 weeks, without compromising renal function or causing serious adverse events."

Journal • Diabetes • Hypoglycemia • Infectious Disease • Metabolic Disorders • Nephrology • Type 2 Diabetes Mellitus

Re: Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus. (PubMed, Sultan Qaboos Univ Med J) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Safety and Efficacy of Remogliflozin in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. (PubMed, Cureus) - "The results were accompanied by high heterogeneity, which necessitates conducting high-quality randomized control trials for more robust evidence synthesis. Overall Remogliflozin can be considered a safe drug with beneficial effects on body weight and HDL-C levels for the treatment of people with T2DM."

Journal • Retrospective data • Review • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Stability-Indicating Green HPLC Method for Fixed-Dose Tablets Containing Remogliflozin Etabonate and Teneligliptin: An AQbD Approach. (PubMed, Drug Dev Ind Pharm) - "The AGREE score of 0.65 supports its green applicability for tablet analysis in quality control. The AQbD-assisted RP-HPLC method developed in this study offers environmental friendliness, efficient separation with well-defined peaks, and simple mobile phase combination."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Are two Gliflozins different: A Prospective Multicenter Randomized Study to Assess Effect of Remogliflozin compared to Empagliflozin on Biomarkers of Heart Failure in Indian Patients of Type 2 diabetes mellitus with Chronic Heart Failure (REMIT-HF study). (PubMed, J Card Fail) - "Remogliflozin and Empagliflozin significantly improves glycemic parameters and NT-proBNP levels as the index of the therapeutic effects in T2DM patients with CHF. The positive effects are comparable in both groups."

Biomarker • Journal • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus

Effect of Remogliflozin in Improving NYHA Class Compared with Empagliflozin in Type 2 Diabetes Patients with Heart Failure (Remit HF) (ADA 2024) - "The improvement in NYHA class was comparable between Remogliflozin and Empagliflozin in patients of T2DM patients and HF (HFrEF). These clinical benefits were irrespective of baseline NYHA class and was associated with early and sustained improvement in NYHA class over study duration."

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Stability-Indicating HPLC for Remogliflozin, Vildagliptin, and Metformin: Method Development, Validation, and Greenness. (PubMed, Ann Pharm Fr) - "The technique was quick, precise, sensitive, and accurate; as a result, it may be used in quality control laboratories and the pharmaceutical industry for routine quality monitoring of tablets containing all three medications."

Journal

Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus: An open-label comparative study. (PubMed, Sultan Qaboos Univ Med J) - "Both treatments were well tolerated throughout the study. Compared to vildagliptin, remoglilflozin was significantly more effective in glycaemic control and weight loss in patients with T2DM and can therefore be considered as an add-on drug in T2DM not adequately controlled by metformin monotherapy."

Clinical • Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

EFFECT OF REMOGLIFLOZIN ON BIOMARKERS COMPARED TO EMPAGLIFLOZIN INPATIENTS OF TYPE 2 DIABETES MELLITUS WITH CHRONIC HEART FAILURE(REMIT HF) (ACC 2024) - "Remogliflozin significantly improved glycaemic parameters and NT-proBNP as index of therapeutic effects in T2DM patients with HFrEF.Twice daily dosing of Remogliflozin was found to be well tolerated and non-inferior to Empagliflozin in patients of T2DM with HFrEF."

Biomarker • Clinical • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus

Quality by Design Tool Assessed Ultraperformance Liquid Chromatography Method for the Analysis of Remogliflozin and Teneligliptin in Oral Dosage Form. (PubMed, ACS Omega) - "Studies of force degradation proved the stability indicating the nature of the method. A factorial design was used to evaluate the method performance."

Journal

Impacts of trelagliptin and remogliflozin alone and in combination with Alpha Lipoic Acid on cardiac function in streptozotocin-induced diabetes mellitus in rats. (PubMed, Cell Mol Biol (Noisy-le-grand)) - "The combination of trelagliptin, remogliflozin, and ALA may have additional clinical value in managing DCM by targeting oxidative stress, inflammation, and glucotoxicity. However, further research is needed to validate these findings and explore their potential clinical applications."

Biomarker • Combination therapy • Journal • Preclinical • Cardiomyopathy • Cardiovascular • Diabetes • Inflammation • Metabolic Disorders • Myositis • CTSB • NFKB1 • TXNIP

Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials. (PubMed, Front Endocrinol (Lausanne)) - "Compared to placebo, a significantly higher risk of RTIs was observed with canagliflozin, ertugliflozin, empagliflozin, remogliflozin, dapagliflozin, and sotagliflozin, but not with luseogliflozin and ipragliflozin, regardless of gender. The findings guide the selection of SGLT-2 inhibitors for patients with T2DM based on the patient's profiles to maximize safety. https://www.crd.york.ac.uk/prospero, identifier CRD42022334644."

Clinical • Retrospective data • Review • Acute Kidney Injury • Diabetes • Infectious Disease • Metabolic Disorders • Musculoskeletal Diseases • Nephrology • Orthopedics • Renal Disease • Severe Hypoglycemia • Type 2 Diabetes Mellitus

Dose-dependent renoprotection efficacy of sglt2 inhibitors in type 2 diabetes: systematic review and network meta-analysis. (PubMed, Acta Diabetol) - "The renoprotective efficacy of SGLT2i is independent of the incremental doses suggesting lower doses may suffice for renal outcomes."

Journal • Retrospective data • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

EFFECT OF REMOGLIFLOZIN ON BIOMARKERS COMPARED TO EMPAGLIFLOZIN INPATIENTS OF TYPE 2 DIABETES MELLITUS WITH CHRONIC HEART FAILURE (ACC-WCC 2023) - "Remogliflozin improved glycaemic parameters and NTproBNP as an index of therapeutic effects in T2DM patients with CHF. Remogliflozin was well tolerated and non-inferior to Empagliflozin in T2DM patients with CHF."

Biomarker • Clinical • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus • NPPB

Multivariate Analysis and Response Surface Modelling to Green Analytical Chemistry-based RP-HPLC-PDA Method for Chromatographic Analysis of Vildagliptin and Remogliflozin Etabonate. (PubMed, J AOAC Int) - "Development of green and robust RP-HPLC method for estimation of VDG and RGE using safe organic solvents. The AQbD approach has been implemented in the development of a method to minimize solvent wastage. The method was applied for the assay of FDCs of VDG and RGE."

Journal

LV mass reduction in Hypertensive T2DM patients with SGLT2 inhibitors - comparison of Dapagliflozin with Remogliflozin (IDF 2022) - No abstract available

Clinical • Metabolic Disorders • Type 2 Diabetes Mellitus

Chemometric-based AQbD and Green Chemistry Approaches to Chromatographic Analysis of Remogliflozin Etabonate and Vildagliptin. (PubMed, J AOAC Int) - "Chromatographic analysis of vildagliptin and remogliflozin etabonate using green chemistry and AQbD approaches. Application of the method for assay of drugs in their combined pharmaceutical dosage forms."

Journal

A Comparative Study of efficacy and safety of different Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitors in the Management of Patients with Type II Diabetes Mellitus. (PubMed, J Assoc Physicians India) - "Overall observations indicate that all the four SGLT2 inhibitors are effective in reducing HbA1c, FBS, PPBS, body weight SBP, and DBP. Therefore, gliflozins can be the best choice to start early in patients with inadequately controlled T2DM receiving triple-drug therapy which helps in controlling the parameters of glycemia and significantly reducing the body weight. Hence SGLT2 Inhibitors could be considered as an add-on to all antidiabetic agents currently used for the management of diabetes in Indian setting."

Clinical • Journal • Diabetes • Infectious Disease • Metabolic Disorders • Mycosis Fungoides • Nephrology • Type 2 Diabetes Mellitus

An Experimental Design Approach to Quantitative Expression for Quality Control of a Multicomponent Antidiabetic Formulation by the HILIC Method. (PubMed, Molecules) - "A rapid and reproducible hydrophilic liquid chromatography (HILIC) process was established for concomitant determination of remogliflozin etabonate (RE), vildagliptin (VD), and metformin (MF) in a formulation. Utilization of the optimized HILIC procedure for concurrent quantification of RE, VD, and MF in solid dosage forms showed accurate and reproducible results. Hence, the fast HILIC method can be regularly employed for the quality assurance of pharmaceutical preparations comprising RE, VD, and MF."

Journal

Environmental sustainable mathematically processed UV spectroscopic methods for quality control analysis of remogliflozin and teneligliptin: Evaluation of greenness and whiteness. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc) - "Further, recently developed AGREE, Hexagonal greenness and white analytical chemistry, a whiteness evaluation tools were applied to the proposed UV spectroscopic methods and found to be safer analytical methods, compared to the reported expensive, time-consuming and toxic HPLC method. Hence, proposed UV spectroscopic methods could be used for routine quality control of formulations containing REM and TEN."

Journal

Simple and Sensitive RP-HPLC and UV Spectroscopic Methods for the Determination of Remogliflozin Etabonate in Pure and Pharmaceutical Formulations (PubMed, Turk J Pharm Sci) - "The RT of RMZ and internal standard, atorvastatin (ATST) were 6.2 min and 7.0 min, respectively. The developed methods were found to be simple, accurate, reproducible, and precise. The RMZ can be analyzed in dual techniques, i.e., chromatographic and UV spectroscopic methods for its routine analysis."

Journal

Efficacy and Safety of a Fixed Dose Combination of Remogliflozin Etabonate and Vildagliptin in Patients with Type-2 Diabetes Mellitus: A Randomized, Active-Controlled, Double-Blind, Phase III Study. (PubMed, J Assoc Physicians India) - "Overall, FDC of Remogliflozin Etabonate + Vildagliptin added on to Metformin was found to be efficacious and well tolerated in the treatment of patients with T2DM, and demonstrated non-inferiority to Empagliflozin 25mg + Linagliptin 5mg treatment added on to Metformin."

Journal • P3 data • Diabetes • Hypoglycemia • Infectious Disease • Metabolic Disorders • Nephrology • Type 2 Diabetes Mellitus